Sagetis Biotech announces the appointment of Dr. Ramon Alemany as a member of its Scientific Advisor
Barcelona, July 4 2017 - Sagetis Biotech, a pioneer in the development of innovative coated virotherapies for treatment of cancer, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of Dr. Ramon Alemany.
Dr. Alemany is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has more than 80 original publications and numerous patents in the fields of Gene Therapy and Virotherapy. From 1994 to 2001, Dr. Alemany held various research positions in USA at the MD Anderson Cancer Center (Houston, TX), Baxter Healthcare (Round Lake, IL), and the University of Alabama at Birmingham. He established the Virotherapy Group at the Translational Research Laboratory of the Institut Català d'Oncologia in 2001.
“We are very pleased to welcome Dr. Alemany as member of Sagetis’ Advisory Board” said Eduard Diviu, Chief Executive Officer of Sagetis Biotech. “Dr. Alemany’s experience in the field of oncolytic adenoviruses will be of great value as we are progressing towards clinical testing of our lead product SAG-101 in pancreatic cancer patients”.
Dr. Ramon Alemany will join existing members of Sagetis SAB: Dr. Cristina Fillat, Gene Therapy and Cancer Principal Investigator at IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Prof. Salvador Borrós, Co-founder, member of the Board at Sagetis Biotech and Full Professor at IQS and Dr. Robert Elfont, John-Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology.
“I’m very happy to join Sagetis’ Advisory Board and support the company in the development of its promising candidate. This polymeric coating technology has the potential to overcome many of the limitations that we see today in systemically administered oncolytic virotherapy and unlock its full potential”
About Sagetis Biotech
Sagetis Biotech is devoted to developing an innovative polymeric technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors.
Privately funded and based in Barcelona, Sagetis Biotech is developing SAG-101: a polymer-coated adenovirus for the treatment of pancreatic ductal adenocarcinoma.